Olive Fruit Extract
Olea europaea
Also known as: Olive polyphenols, Hydroxytyrosol-rich olive extract
This ingredient is classified as unclassified risk (GIRI score: 1.5/10).
Safety Profile
Information not yet available for this ingredient profile.
Interactions
Information not yet available for this ingredient profile.
Evidence and Scientific Findings
Ingredient Overview
Olive fruit extract is rich in polyphenols including hydroxytyrosol and oleuropein. It has an excellent safety record as a food-derived compound. High supplemental doses may mildly lower blood pressure, requiring caution with antihypertensives. Allergic reactions are rare.
Biological and Chemical Classification
- Scientific Name
- Olea europaea
Mechanism of Action
Information not yet available for this ingredient profile.
Clinical Evidence of Effectiveness
Information not yet available for this ingredient profile.
Pharmacokinetics
Information not yet available for this ingredient profile.
Recommended Dosage
Information not yet available for this ingredient profile.
SETI — Scientific Evidence Transparency Index
Executive Summary — Ingredient Assessment
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or RCT)
- Main clinical benefit observed: Antioxidants
- Evidence consistency: High consistency across studies (100%)
- No significant safety signals identified in the reviewed literature.
The available scientific evidence for Olive Fruit Extract indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.
Total SETI Score
High risk| Evidence quality | 10/40 |
| Evidence consistency | 20/20 |
| Safety signals | 0/20 |
| Study recency | 10/10 |
| Evidence transparency | 10/10 |
Evidence Summary
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or systematic review)
- 0 studies identified benefits or no safety concern (GREEN)
- 10 studies reported limited or advisory safety evidence (YELLOW)
Evidence Policy
Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.
Last updated: 26 მარ 2026, 14:01
Evidence Distribution
-
Observational / other LOW evidence YELLOWTherapeutic potential of Olea europaea leaf extract in preventing isoproterenol-induced myocardial injury: integrated biochemical, LC-MS profiling, and molecular docking analyses. ↗Benameur M et al.. Therapeutic potential of Olea europaea leaf extract in preventing isoproterenol-induced myocardial injury: integrated biochemical, LC-MS profiling, and molecular docking analyses.. J Ethnopharmacol. 2026. PMID:41881322.PMID 41881322 ↗Journal J EthnopharmacolYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41881322/
-
Observational / other LOW evidence YELLOWResisting Xylella fastidiosa: xylem anatomical changes in the susceptible olive cultivar Cellina di Nardu00f2 after long-term infection. ↗Sabella E et al.. Resisting Xylella fastidiosa: xylem anatomical changes in the susceptible olive cultivar Cellina di Nardu00f2 after long-term infection.. Plant Biol (Stuttg). 2026. PMID:41880764.PMID 41880764 ↗Journal Plant Biol (Stuttg)Year 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41880764/
-
Observational / other LOW evidence YELLOWOliveNet 2.0: Chemical library of compounds from Olea europaea and utilisation for in silico modelling in the context of metabolic disorders targeting… ↗Pitsillou E et al.. OliveNet 2.0: Chemical library of compounds from Olea europaea and utilisation for in silico modelling in the context of metabolic disorders targeting the MTHFR protein.. J Mol Graph Model. 2026. PMID:41830707.PMID 41830707 ↗Journal J Mol Graph ModelYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41830707/
-
Observational / other LOW evidence YELLOWLC-MS/MS Analysis and Preliminary Screening of Antidiabetic, Anti-Obesity, and Antioxidant Activities of Selected Turkish Plants. ↗u00d6zu00fcpek B et al.. LC-MS/MS Analysis and Preliminary Screening of Antidiabetic, Anti-Obesity, and Antioxidant Activities of Selected Turkish Plants.. Chem Biodivers. 2026. PMID:41830527.PMID 41830527 ↗Journal Chem BiodiversYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41830527/
-
Observational / other LOW evidence YELLOWPollinizer' Effects on Olive Seed Set, Size and Abortion. ↗Cuevas J et al.. Pollinizer' Effects on Olive Seed Set, Size and Abortion.. Plants (Basel). 2026. PMID:41829843.PMID 41829843 ↗Journal Plants (Basel)Year 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41829843/
-
Observational / other LOW evidence YELLOWAutomatic monitoring and imaging-based identification of airborne Olea pollen. ↗Farooq Q et al.. Automatic monitoring and imaging-based identification of airborne Olea pollen.. Environ Res. 2026. PMID:41825553.PMID 41825553 ↗Journal Environ ResYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41825553/
-
Observational / other LOW evidence YELLOWA lightweight YOLO-TinyFuse model for small target detection of olive fruits. ↗Yang X et al.. A lightweight YOLO-TinyFuse model for small target detection of olive fruits.. Front Plant Sci. 2026. PMID:41815435.PMID 41815435 ↗Journal Front Plant SciYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41815435/
-
Observational / other LOW evidence YELLOWModes of Action and In Planta Antifungal Activity of Olea europaea Defensin OefDef1.1-Derived Peptide Variant. ↗Tiwari R et al.. Modes of Action and In Planta Antifungal Activity of Olea europaea Defensin OefDef1.1-Derived Peptide Variant.. Mol Plant Microbe Interact. 2026. PMID:41812637.PMID 41812637 ↗Journal Mol Plant Microbe InteractYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41812637/
-
Observational / other LOW evidence YELLOWAntioxidant and Cytoprotective Effects of Herbal Extract-Enriched Artificial Saliva: In-Vitro Biocompatibility and Cell Culture Studies. ↗Erten Can H et al.. Antioxidant and Cytoprotective Effects of Herbal Extract-Enriched Artificial Saliva: In-Vitro Biocompatibility and Cell Culture Studies.. Oral Health Prev Dent. 2026. PMID:41810717.PMID 41810717 ↗Journal Oral Health Prev DentYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41810717/
-
Observational / other LOW evidence YELLOWSupercritical fluid extraction method for multi class bioactives: a sustainable approach to Olea europaea pruning residue valorization. ↗Cafeo G et al.. Supercritical fluid extraction method for multi class bioactives: a sustainable approach to Olea europaea pruning residue valorization.. Talanta. 2026. PMID:41797171.PMID 41797171 ↗Journal TalantaYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41797171/
Score Transparency
0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.
Method: Q = number of approved references ÷ 10 (capped at 1.0)
Limited — mostly case reports or animal studies
Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.
Mixed or neutral — roughly equal benefit and risk signals
Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.
One or more monitoring-level safety signals active
Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.
Final GIRI Score for Olive Fruit Extract. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
Full methodology & data sources
The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.
- References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
- Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
- Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
- Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
Risk Level Classification
Based on available regulatory signals and scientific evidence, this ingredient presents a low safety concern under normal conditions of use.
0–3.0
3.0–5.5
5.5–7.5
7.5–10
The score pin shows exactly where this ingredient falls on the fixed risk scale.
What drove the Low classification for Olive Fruit Extract
A score of 1.5 places this ingredient in the Low band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
0 approved references.
Limited — mostly case reports or animal studies (Level 4–5).
Neutral or mixed — benefit and risk signals roughly balanced.
No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.
No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).
How are the Low / Moderate / High / Critical thresholds defined?
The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:
| Level | Score | Meaning |
|---|---|---|
| LOW | 0.0 – 2.9 | Sparse or predominantly beneficial evidence. No active safety alerts. |
| MODERATE | 3.0 – 5.4 | Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups. |
| HIGH | 5.5 – 7.4 | Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended. |
| CRITICAL | 7.5 – 10 | Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision. |
Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.